Table 1.
Demographic and clinical characteristics of patients at baseline
| Characteristic | Patient group | |
|---|---|---|
| All | Acquired T790M | |
| Total, n (%) | 67 (100) | 49 (73.1) |
| Median age, years (range) | 67 (36–87) | 70 (44–87) |
| Sex, n (%) | ||
| Female | 49 (73.1) | 39 (79.6) |
| Male | 18 (29.6) | 10 (20.4) |
| Race, n (%) | ||
| Caucasian | 62 (92.5) | 45 (91.8) |
| Asian | 5 (7.5) | 4 (8.2) |
| Smoking status, n (%) | ||
| Never-smokers | 49 (73.1) | 38 (77.6) |
| Ex-smokers | 13 (19.4) | 8 (16.3) |
| Smokers | 5 (7.5) | 3 (6.1) |
| Brain metastases, n (%) | 14 (20.9) | 9 (18.4) |
| EGFR mutation at baseline (prior to any systemic therapy), n (%) | ||
| Exon 19 deletion | 38 (56.7) | 30 (61.2) |
| L858R | 17 (25.4) | 14 (28.6) |
| G719X | 3 (4.5) | 1 (2.0) |
| L861Q | 4 (6.0) | 1 (2.0) |
| Other | 5 (7.5)a | 3 (6.1)b |
| Treatment prior to afatinib, n (%) | ||
| First-generation EGFR TKIc | 9 (13.4) | 9 (18.4) |
| Platinum-based chemotherapyd | 1 (1.5) | 1 (2.0) |
| Chemotherapy and EGFR TKIe | 3 (4.5) | 3 (6.1) |
| Afatinib treatment line, n (%) | ||
| First | 54 (80.6) | 36 (73.5) |
| Second | 10 (14.9) | 10 (20.4) |
| Third | 3 (4.5) | 3 (6.1) |
aExon 20 insertions (n = 2), L858R/G719X (n = 1), G719X/S786I (n = 1), G719X/L861Q (n = 1)
bExon 20 insertion (n = 1), L858R/G719X (n = 1), G719X/S786I (n = 1)
cErlotinib (n = 1) and gefitinib (n = 8)
dCarboplatin/pemetrexed (n = 1)
eCisplatin/pemetrexed followed by erlotinib (n = 1), gefitinib followed by cisplatin/pemetrexed/bevacizumab (n = 1), gefitinib followed by pemetrexed (n = 1)